Friday, September 29, 2023
HitGen has announced a strategic partnership with the Structural Genomics Consortium (SGC) with the aim of accelerating the discovery of new medicines through open-access research.
In this collaboration, HitGen will leverage its cutting-edge DNA-encoded library (DEL) technology platform, specifically known as OpenDEL™, to conduct screenings on targets that have been historically underrepresented in research, as selected by SGC.
OpenDEL™, a key component of this collaboration, is a self-service DEL kit boasting an extensive library of over 3 billion compounds. OpenDEL™ has the unique capability to allow users to conduct DEL selection campaigns without revealing the identity of the target protein.
Users, guided by comprehensive manuals and operating instructions, can employ OpenDEL™ to perform affinity screening experiments against specific protein targets within their own laboratory settings. In addition, HitGen will provide essential technical support both upstream and downstream in the research process.
This partnership holds significant transformative potential, as it will furnish the ML community with high-quality, well-curated data. This data will enable ML experts to actively contribute to the global effort to identify promising drug starting points for all human proteins.
Through close collaboration with SGC's research teams, this partnership endeavours to generate novel starting points for proteins that have been historically under-studied.
